PD-1 anticorps (AA 201-288) (Cy5)

N° du produit ABIN735612

Cet anticorps anti-PD-1 est un anticorps Lapin Polyclonal détectant PD-1 dans FACS, WB, IF (cc) et IF (p). Adapté pour Humain, Souris et Rat.

Aperçu rapide pour PD-1 anticorps (AA 201-288) (Cy5) (ABIN735612)

Antigène: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PD-1 est conjugé à/à la Cy5

Application: Flow Cytometry (FACS), Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Détail du produit anti-PD-1 anticorps (Cy5)

Épitope: AA 201-288

Réactivité croisée: Humain, Souris, Rat

Homologie: Cow,Horse,Rabbit

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human PD-1

Isotype: IgG

Information d'application

Indications d'application: FCM 1:20-100
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur PD-1

Antigène: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Autre désignation: Pd-1/Cd279

Sujet:

Synonyms: PD1, PD-1, CD279, SLEB2, hPD-1, hPD-l, hSLE1, Programmed cell death protein 1, Protein PD-1, PDCD1

Background: Inhibitory cell surface receptor involved in the regulation of T-cell function during immunity and tolerance. Upon ligand binding, inhibits T-cell effector functions in an antigen-specific manner. Possible cell death inducer, in association with other factors.

ID gène: 5133

UniProt: Q15116

Pathways: Cancer Immune Checkpoints